Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Research — Clinical trials, evidence maturity, genomics, health equity, and patient empowerment baselines.

Research workspace

Analyst sandbox

rNPV scenario and Monte Carlo sandbox

Explore how development risk, commercial assumptions, timing, and capital requirements change a hypothetical asset value. The figures are assumptions you enter. They are separate from the curated deal dataset.

Analyst scenario sandbox for researchers and early-stage teams. It explores how development risk, commercial assumptions, timing, and capital needs change a hypothetical asset value. It is not an investment recommendation, a clinical prediction, a company ranking, or a verified valuation. Outputs stay on this page and do not feed Lacuna deal scores or verified records. No live data or model service is used.

Hypothetical rNPV assumptions

The form starts blank. Load the illustrative preset, or type your own hypothetical assumptions. Nothing here is observed company data.

Remaining development

Conditional success is the chance of finishing a stage after entering it. Future cost is spread evenly to each year-end of that stage and is paid in full once the stage is entered, including paths that later fail.

Preclinical risk and cost are excluded. To model them, choose Preclinical and enter your own success rate, duration, cost, and rationale.

Phase I
Phase II
Phase III
Regulatory submission
Discounting and capital
Commercial cash-flow assumptions
Monte Carlo uncertainty

Each path succeeds or fails stage by stage. Later costs stop after a failure. Path results are not multiplied by the success rate again. Zero ranges isolate that development risk. Positive ranges are independent uniform analyst choices, not estimated confidence intervals. Durations, margin, tax, upfront cost, and the sales shape stay fixed.

Method and limitations

Amounts are USD millions. The valuation date is entry into the selected stage. A certain upfront cost is paid at that date and is not discounted. Remaining stage costs are equal year-end installments, weighted in the expected-value view by the share of paths that enter the stage. Failure is recognized at the stage end and cancels every later cost. Launch investment is paid at the development-completion year-end only on success. First revenue is one year later.

Sales rise linearly to the peak in the final ramp year, stay there for the additional peak years, then decline geometrically. Commercial cash flow is sales times operating cash margin times one minus the tax rate. There is no terminal value, intra-stage stopping, royalty, milestone, tax-loss carryforward, dilution, or financing bridge.

The Monte Carlo draws Bernoulli stage outcomes and does not re-weight those paths by the success rate again. Positive uncertainty ranges are independent and uniform. They are not empirical posteriors. The reported sampling interval is finite-simulation error only.